High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions
Abstract Background ETS2 is a downstream effector of the RAS/RAF/ERK pathway, which plays a critical role in the development of malignant tumor. However, the clinical impact of ETS2 expression in AML remains unknown. Methods In this study, we evaluated the prognostic significance of ETS2 expression...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-07-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12967-017-1260-2 |
| _version_ | 1811282602211934208 |
|---|---|
| author | Lin Fu Huaping Fu Qingyun Wu Yifan Pang Keman Xu Lei Zhou Jianlin Qiao Xiaoyan Ke Kailin Xu Jinlong Shi |
| author_facet | Lin Fu Huaping Fu Qingyun Wu Yifan Pang Keman Xu Lei Zhou Jianlin Qiao Xiaoyan Ke Kailin Xu Jinlong Shi |
| author_sort | Lin Fu |
| collection | DOAJ |
| description | Abstract Background ETS2 is a downstream effector of the RAS/RAF/ERK pathway, which plays a critical role in the development of malignant tumor. However, the clinical impact of ETS2 expression in AML remains unknown. Methods In this study, we evaluated the prognostic significance of ETS2 expression using two relatively large cohorts of AML patients. Results In the first cohort, compared to low expression of ETS2 (ETS2 low), high expression of ETS2 (ETS2 high) showed significant shorter OS, EFS and RFS in the current treatments including the allogeneic HCT group (n = 72) and the chemotherapy group (n = 100). Notably, among ETS2 high patients, those received allogeneic HCT had longer OS, EFS and RFS than those with chemotherapy alone (allogeneic HCT, n = 39 vs. chemotherapy, n = 47), but treatment modules play insignificant role in the survival of ETS2 low patients (allogeneic HCT, n = 33 vs. chemotherapy, n = 53). Moreover, gene/microRNA expression data provides insights into the biological changes associated with varying ETS2 expression levels in AML. The prognostic value of ETS2 was further validated in the second AML cohort (n = 329). Conclusions Our results indicate that ETS2 high is a poor prognostic factor in AML and may guide treatment decisions towards allogeneic HCT. |
| first_indexed | 2024-04-13T01:55:32Z |
| format | Article |
| id | doaj.art-f234f8656be44aed8dd9f9a139bbb371 |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-04-13T01:55:32Z |
| publishDate | 2017-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-f234f8656be44aed8dd9f9a139bbb3712022-12-22T03:07:47ZengBMCJournal of Translational Medicine1479-58762017-07-011511910.1186/s12967-017-1260-2High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisionsLin Fu0Huaping Fu1Qingyun Wu2Yifan Pang3Keman Xu4Lei Zhou5Jianlin Qiao6Xiaoyan Ke7Kailin Xu8Jinlong Shi9Department of Hematology and Lymphoma Research Center, Peking University, Third HospitalDepartment of Nuclear Medicine, Chinese PLA General HospitalDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Medicine, Wil-liam Beaumont HospitalNortheastern UniversityDepartment of Hematology, Chinese PLA General HospitalDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Hematology and Lymphoma Research Center, Peking University, Third HospitalDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical UniversityDepartment of Hematology, Huaihe Hospital of Henan UniversityAbstract Background ETS2 is a downstream effector of the RAS/RAF/ERK pathway, which plays a critical role in the development of malignant tumor. However, the clinical impact of ETS2 expression in AML remains unknown. Methods In this study, we evaluated the prognostic significance of ETS2 expression using two relatively large cohorts of AML patients. Results In the first cohort, compared to low expression of ETS2 (ETS2 low), high expression of ETS2 (ETS2 high) showed significant shorter OS, EFS and RFS in the current treatments including the allogeneic HCT group (n = 72) and the chemotherapy group (n = 100). Notably, among ETS2 high patients, those received allogeneic HCT had longer OS, EFS and RFS than those with chemotherapy alone (allogeneic HCT, n = 39 vs. chemotherapy, n = 47), but treatment modules play insignificant role in the survival of ETS2 low patients (allogeneic HCT, n = 33 vs. chemotherapy, n = 53). Moreover, gene/microRNA expression data provides insights into the biological changes associated with varying ETS2 expression levels in AML. The prognostic value of ETS2 was further validated in the second AML cohort (n = 329). Conclusions Our results indicate that ETS2 high is a poor prognostic factor in AML and may guide treatment decisions towards allogeneic HCT.http://link.springer.com/article/10.1186/s12967-017-1260-2ETS2PrognosisAMLAllogeneic HCT |
| spellingShingle | Lin Fu Huaping Fu Qingyun Wu Yifan Pang Keman Xu Lei Zhou Jianlin Qiao Xiaoyan Ke Kailin Xu Jinlong Shi High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions Journal of Translational Medicine ETS2 Prognosis AML Allogeneic HCT |
| title | High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions |
| title_full | High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions |
| title_fullStr | High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions |
| title_full_unstemmed | High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions |
| title_short | High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions |
| title_sort | high expression of ets2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions |
| topic | ETS2 Prognosis AML Allogeneic HCT |
| url | http://link.springer.com/article/10.1186/s12967-017-1260-2 |
| work_keys_str_mv | AT linfu highexpressionofets2predictspoorprognosisinacutemyeloidleukemiaandmayguidetreatmentdecisions AT huapingfu highexpressionofets2predictspoorprognosisinacutemyeloidleukemiaandmayguidetreatmentdecisions AT qingyunwu highexpressionofets2predictspoorprognosisinacutemyeloidleukemiaandmayguidetreatmentdecisions AT yifanpang highexpressionofets2predictspoorprognosisinacutemyeloidleukemiaandmayguidetreatmentdecisions AT kemanxu highexpressionofets2predictspoorprognosisinacutemyeloidleukemiaandmayguidetreatmentdecisions AT leizhou highexpressionofets2predictspoorprognosisinacutemyeloidleukemiaandmayguidetreatmentdecisions AT jianlinqiao highexpressionofets2predictspoorprognosisinacutemyeloidleukemiaandmayguidetreatmentdecisions AT xiaoyanke highexpressionofets2predictspoorprognosisinacutemyeloidleukemiaandmayguidetreatmentdecisions AT kailinxu highexpressionofets2predictspoorprognosisinacutemyeloidleukemiaandmayguidetreatmentdecisions AT jinlongshi highexpressionofets2predictspoorprognosisinacutemyeloidleukemiaandmayguidetreatmentdecisions |